Key Points
- CEO Neil Mcfarlane sold 91,000 shares on Feb. 2 at an average price of $9.38 for proceeds of $853,580, cutting his stake by 19.98% to 364,350 shares (disclosed in an SEC filing).
- Shares trade around $9.36 with a market cap of about $526.95M, a 50‑day/200‑day moving average of $8.66/$9.43 and a one‑year range of $6.19–$13.16.
- Analysts hold a consensus "Moderate Buy" with an average target of $22.80 (six Buys, one Hold, one Sell); the company recently reported an EPS beat (‑$0.01 vs. est. ‑$0.04) while revenue of $26.06M slightly missed expectations.
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) SVP Timothy Sangiovanni sold 1,750 shares of the firm's stock in a transaction that occurred on Friday, January 30th. The stock was sold at an average price of $8.82, for a total value of $15,435.00. Following the transaction, the senior vice president owned 20,924 shares in the company, valued at $184,549.68. This represents a 7.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Zevra Therapeutics Price Performance
Shares of NASDAQ ZVRA opened at $9.36 on Tuesday. The stock has a market cap of $526.95 million, a P/E ratio of 19.91 and a beta of 1.08. Zevra Therapeutics, Inc. has a twelve month low of $6.19 and a twelve month high of $13.16. The stock has a 50 day moving average of $8.66 and a two-hundred day moving average of $9.43. The company has a current ratio of 8.62, a quick ratio of 8.57 and a debt-to-equity ratio of 0.46.
Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its earnings results on Wednesday, November 5th. The company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.03. Zevra Therapeutics had a net margin of 41.93% and a negative return on equity of 51.40%. The business had revenue of $26.06 million for the quarter, compared to analysts' expectations of $26.64 million. On average, research analysts forecast that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on ZVRA shares. Wall Street Zen raised Zevra Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, November 8th. HC Wainwright set a $26.00 target price on Zevra Therapeutics in a research note on Tuesday, December 30th. Cantor Fitzgerald dropped their target price on Zevra Therapeutics from $29.00 to $24.00 and set an "overweight" rating on the stock in a report on Thursday, November 6th. Canaccord Genuity Group cut their price target on Zevra Therapeutics from $25.00 to $24.00 and set a "buy" rating for the company in a research note on Thursday, November 6th. Finally, Weiss Ratings reiterated a "sell (d+)" rating on shares of Zevra Therapeutics in a research report on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Zevra Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $22.80.
Read Our Latest Stock Analysis on ZVRA
Institutional Trading of Zevra Therapeutics
A number of institutional investors have recently modified their holdings of ZVRA. Marshall Wace LLP purchased a new position in Zevra Therapeutics in the third quarter worth $8,676,000. Rubric Capital Management LP grew its stake in shares of Zevra Therapeutics by 60.8% during the 2nd quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company's stock worth $17,253,000 after purchasing an additional 740,584 shares during the period. Royce & Associates LP purchased a new position in shares of Zevra Therapeutics in the 3rd quarter valued at about $6,574,000. Adage Capital Partners GP L.L.C. increased its holdings in shares of Zevra Therapeutics by 15.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company's stock valued at $36,720,000 after purchasing an additional 550,000 shares in the last quarter. Finally, Nantahala Capital Management LLC lifted its stake in shares of Zevra Therapeutics by 34.0% in the third quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company's stock valued at $18,753,000 after purchasing an additional 500,000 shares during the period. 35.03% of the stock is currently owned by hedge funds and other institutional investors.
Zevra Therapeutics Company Profile
(
Get Free Report)
Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
